Merrill reiterates New River at buy

New River Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst David Munno at a buy on news that the company's New Drug Applications for NRP104 for attention deficit hyperactivity disorder was accepted for filing with standard review. Merrill looks for the product to lunch by the end of the year. Shares of the Radford, Va., pharmaceutical company were up 60 cents, or 1.83%, at $33.40 on volume of 167,051 shares versus the three-month running average of 255,179 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.